Systems Biology of Zoster Vaccine

Status Completed

Clinical Trial Summary

The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.

Clinical Trial Description

Varicella zoster virus (VZV) can cause two distinct diseases: chicken pox (varicella) and herpes zoster (shingles). The primary infection with VZV causes chicken pox, a widespread rash occurring with fever, mostly in childhood. The virus can then remain dormant in a person's body and has the ability to reactivate later in life causing shingles. Shingles is a painful rash, occurring mostly in older individuals or those who have a weakened immune system. After resolution of the rash, individuals may experience persistent pain in the same area, called post-herpetic neuralgia. The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). In particular, looking at certain markers in the blood after vaccination with Shingrix®. The study will be an open label clinical trial in healthy older adults. There will be two groups of participants: those aged 50 to 60 years or those who are 70 years old and above, both groups will receive the vaccine. This will help compare the immune response to the herpes zoster vaccine in different age cohorts of older adults. Subjects will be recruited by flyer advertisements. Interested individuals will be screened for the study and if they qualify they will be consented and enrolled in the study. Blood samples will be collected and banked. There are optional storage of data/specimens for future research including: being contacted for future studies, having contact information and limited medical information entered into a clinic database, and storage of Protected Health Information and samples for future research (yes, no, and de-identified). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04047979
Study type	Interventional
Source	Emory University
Contact
Status	Completed
Phase	Phase 2
Start date	November 14, 2019
Completion date	October 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01132716` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions	N/A
Completed	`NCT01132729` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions	N/A
Completed	`NCT04099706` - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT	N/A
Completed	`NCT04540081` - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer	N/A
Completed	`NCT01527370` - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)	Phase 3
Completed	`NCT00534248` - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)	Phase 3
Completed	`NCT01262300` - Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents	Phase 1
Completed	`NCT00576108` - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)	Phase 2
Completed	`NCT00109122` - Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)	Phase 2
Active, not recruiting	`NCT05871541` - A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine	Phase 1
Completed	`NCT02114333` - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds	Phase 1
Completed	`NCT00900783` - A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster	Phase 2
Completed	`NCT01600079` - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Active, not recruiting	`NCT02444936` - ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors	Phase 4
Recruiting	`NCT05554068` - Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients	Phase 2
Recruiting	`NCT06238726` - Nudging Patients to Increase Shingles Vaccination	N/A
Completed	`NCT02704572` - Optimal Timing of Zoster Vaccine After Zoster Illness	N/A
Completed	`NCT00300222` - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia	Phase 3
Terminated	`NCT02412917` - A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia	Phase 3
Completed	`NCT00115310` - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia	Phase 3